

Inositol polyphosphate multikinase (ArgRIII) determines nuclear mRNA export in *Saccharomyces cerevisiae*

Adolfo Saiardi^a, James J. Caffrey^b, Solomon H. Snyder^{a,c,d}, Stephen B. Shears^{b,*}

^aDepartment of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

^bInositide Signaling Section, Laboratory of Signal Transduction, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA

^cDepartment of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

^dDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

Received 17 December 1999; received in revised form 24 January 2000

Edited by Horst Feldmann

Abstract The *ARGRIII* gene of *Saccharomyces cerevisiae* encodes a transcriptional regulator that also has inositol polyphosphate multikinase (ipmk) activity [Saiardi et al. (1999) *Curr. Biol.* 9, 1323–1326]. To investigate how inositol phosphates regulate gene expression, we disrupted the *ARGRIII* gene. This mutation impaired nuclear mRNA export, slowed cell growth, increased cellular [InsP₃] 170-fold and decreased [InsP₆] 100-fold, indicating reduced phosphorylation of InsP₃ to InsP₆. Levels of diphosphoinositol polyphosphates were decreased much less dramatically than was InsP₆. Low levels of InsP₆, and considerable quantities of Ins(1,3,4,5)P₄, were synthesized by an ipmk-independent route. Transcriptional control by ipmk reflects that it is a pivotal regulator of nuclear mRNA export via inositol phosphate metabolism.

© 2000 Federation of European Biochemical Societies.

Key words: *ARGRIII*; Inositol polyphosphate multikinase; Inositol phosphate; InsP₆; mRNA export; Yeast

1. Introduction

Several years ago, it was shown that a *Saccharomyces cerevisiae* gene, *ARGRIII*, controls the transcription of several enzymes regulating arginine metabolism [1–3]. In addition, this gene was established to be pleiotropic. This idea recently returned to prominence with the discovery that the *ARGRIII* gene product has inositol polyphosphate multikinase (ipmk) activity, which can catalyze the ATP-dependent phosphorylation of Ins(1,4,5)P₃ and Ins(1,3,4,5)P₄ [4]. These developments suggest that inositol phosphates may mediate some of the functions of *ARGRIII* that relate to transcriptional regulation.

Another recent study [5] also strongly indicates that there is a link between the turnover of inositol phosphates and the regulation of gene expression. In the latter investigation, three *S. cerevisiae* genes were identified which, when deleted, resulted in decreased efficiency of mRNA export from the nucleus via the nuclear pore complex [5]. In one of these mutant yeast strains, named *gsl3*, the deficiency in mRNA export was accompanied by a block in the pathway of InsP₆ synthesis, at the stages at which both InsP₃ and InsP₄ are phosphorylated

[5]. Since the nature of the genetic defect in the *gsl3* yeast strain was not identified, it was speculated that an essential regulator of separate InsP₃ and InsP₄ kinase activities was compromised [5]. Alternately, it was also pointed out that the *gsl3* strain of yeast might be lacking a single, bi-functional kinase activity that phosphorylates both InsP₃ and InsP₄ [5].

We have now pursued the possibility that a loss of the Ins(1,4,5)P₃ and Ins(1,3,4,5)P₄ kinase activities of ipmk could account for the metabolic defect in the *gsl3* strain. We also sought more information concerning the role of the ipmk protein in this newly emerging relationship between inositol phosphate turnover and control over gene expression. By creating and studying a strain of *S. cerevisiae* from which the *ARGRIII* gene is deleted, we reveal new aspects to inositol phosphate turnover in yeast, and we show that ipmk activity regulates nuclear export of mRNA.

2. Materials and methods

2.1. Generation and analysis of *ipmkΔ* yeast

The YDR173C open reading frame (ORF) in *S. cerevisiae* comprises the *ARGRIII* gene that encodes ipmk activity. The entire *ARGRIII* gene in *S. cerevisiae* (strain PJ69-2A), including start and stop codons, was replaced by the dominant *kan^r* marker gene using the KanMX4 expression construct as previously described [6]. The oligonucleotides used for the gene disruption were: 5'-ATGGATA-TGTGCATACGTTGTCCTAAGTAGAAATTTTTTCACGCAT-AGGCCACTAGTGGATCTG-3' and 5'-GTACCATATCCCATAA-ACAAGGTAACCTCACCTCTCAATATACAGCTGAAGCTTC-GTACGC-3'. To confirm the correct integration of the marker gene, diagnostic PCR was performed using the following oligonucleotides: 5'-GATAAAGCCATTGGAGATCC-3' and 5'-AATGCAAACACA-ATAATACC-3'. The sizes of the diagnostic PCR products derived from the wild-type and mutant (*argRIII::KanMX4* or *ipmkΔ*) strains were 1.4 and 1.8 kb, respectively, close to the sizes of the *ARGRIII* gene (1.3 kb) and the *kan^r* gene (1.7 kb). The structures of the PCR products were also verified by direct sequencing.

2.2. Yeast culturing and radiolabeling with [³H]inositol

Yeast cultures were grown in YPD media containing 2% (w/v) glucose. Duplicate 5 ml cultures were seeded at 3 × 10⁴ cells/ml, [³H]inositol (100 μCi/ml, American Radiolabeled Chemicals, MO, USA) was added, and cells were grown at 23°C through at least eight doublings. Cultures were then shifted to 37°C for an additional 2 h. 10⁸ cells were harvested from each culture, washed twice with ice-cold water and snap-frozen until lysis. Cell pellets were lysed in 0.2 ml ice-cold lysis buffer (2 M perchloric acid/0.1 mg/ml InsP₆/2 mM EDTA) with two cycles of vigorous bead beating (4 mm glass beads pre-soaked in lysis buffer). Lysates were centrifuged for 5 min at 4°C and neutralized [7].

Inositol phosphates were then resolved on two complementary high performance liquid chromatography (HPLC) systems [8,9]: (i) a Partisphere SAX HPLC column (Krackler Scientific, NC, USA) was eluted

*Corresponding author. Fax: (1)-919-541 0559.
E-mail: shears@niehs.nih.gov

with a gradient generated by mixing buffer A (1 mM Na₂EDTA) and buffer B (buffer A plus 1.3 M (NH₄)₂HPO₄, pH 3.85, with H₃PO₄) as follows: 0–5 min, 0% B; 5–10 min, 0–50% B; 10–60 min, 50–100% B; 60–70 min, 100% B. (ii) a SynChropak Q100 SAX HPLC column (Thompson Instrument, VA, USA) was eluted with a gradient generated by mixing buffer A (1 mM Na₂EDTA) with buffer B (buffer A plus 2 M (NH₄)₂HPO₄, pH 3.35, with H₃PO₄): 0–5 min, 0% B; 5–120 min, 0–65% B.

Inositol phosphates were identified by their co-elution with the following authentic standards: [³H]Ins(1,4,5)P₃, [³H]Ins(1,3,4,5)P₄ and [³H]InsP₆ (New England Nuclear), [³H]Ins(1,3,4,5,6)P₅ [10], [³H]Ins(1,2,4,5,6)P₅ [11], [³H]PP-InsP₅ and [³H][PP]₂-InsP₄ [12] and [¹⁴C]-labeled Ins(1,3,4,5)P₄, Ins(1,3,4,6)P₄, D/L-Ins(1,4,5,6)P₄ and Ins(1,3,4,5,6)P₅ isolated from [¹⁴C]inositol-labeled, parotid acinar glands [13].

2.3. Assay of *ipmk* activity in vitro

The ORF for *ARGRIII* that encodes *ipmk* activity was recovered from the pCMV-GST vector [4] after digestion with *SalI* and *NotI* restriction enzymes, and subcloned into the *SalI* and *NotI* sites of the pGEX-4T-2 expression vector (Amersham Pharmacia Biotech). The methods used to transform *Escherichia coli* (strain BL21), to induce with IPTG, and to isolate the GST fusion protein using glutathione Sepharose 4B resin were all according to the manufacturer's recommendations (Amersham Pharmacia Biotech). *Ipmk* activity was assayed by incubating the protein for 5–60 min at 37°C with trace amounts (10 000 dpm) of the appropriate ³H-labeled inositol phosphate in 25 μl assays containing 20 mM HEPES (pH 7.0), 12 mM MgSO₄, 10 mM Na₂ATP, 20 mM phosphocreatine, 1 mM DTT, 1 mM EDTA, 360 U phosphocreatine kinase (Calbiochem) and 0.5 mg/ml bovine serum albumin (BSA). Assays were quenched with PCA, neutralized with KCO₃ as described previously [7], and inositol phosphates were resolved by HPLC (see above).

2.4. Localization of poly(A)⁺ RNA by in situ hybridization

Early logarithmic phase cultures of yeast were grown at 23°C before shifting to 37°C for 2 h. Cells were harvested and fixed for 45 min in 4% formaldehyde in 0.1 M phosphate buffer (K⁺ salt, pH 6.5) and washed three times in solution A (1.2 M sorbitol, 0.1 M phosphate buffer (K⁺ salt, pH 7.5)). Cells were treated for 45 min at 30°C in solution A plus 0.1 mg/ml of lyticase (Sigma); resulting spheroplasts were washed in solution A and plated onto a polylysine-coated slide for 45 min at 4°C. Samples were washed and dehydrated in 70% EtOH overnight at –20°C. Samples were treated for hybridization as previously described [14]. Then, samples were washed three times in 2×SSC at 37°C for 10 min, and then three times in 1×SSC at room temperature for 10 min. Cells were permeabilized for 5 min at room temperature in solution B (150 mM NaCl, 100 mM Tris–HCl pH 7.5) containing 0.1% (v/v) Triton X-100, and then washed in solution B and incubated for 1 h at room temperature with anti-digoxigenin-fluorescein Fab fragment (Boehringer Mannheim) in solution B plus 1% (w/v) BSA. The slides were washed at room temperature in solution B for 5 min, then washed in solution B containing 100 ng/ml 4',6-diamidino-2-phenylindole for 10 min, followed by a final wash in 300 mM NaCl, 100 mM Tris–HCl pH 7.5 for 15 min. Photographs were taken with a 60× objective on a Zeiss Axioskop microscope with Kodak Elite 400 film.




Fig. 1. Products of Ins(1,4,5)P₃ phosphorylation by *ipmk* in vitro. [³H]Ins(1,4,5)P₃ was incubated for 0 min (open circles) and 10 min (closed circles) with 2 ng *ipmk* (see Section 2). Samples were quenched and neutralized and chromatographed on a SynChropak Q100 SAX HPLC column (see Section 2); 0.5 ml fractions were collected. The ³H-labeled products, namely, Ins(1,3,4,5)P₄, Ins(1,4,5,6)P₄ and Ins(1,3,4,5,6)P₅, were all identified by their co-elution with internal ¹⁴C-labeled standards (squares) of these three compounds. The elution position of InsP₆ is also indicated by an arrow. Data are representative of three experiments.

3. Results and discussion

3.1. Analysis of *ipmk* activity in vitro

Ipmk was recently shown to phosphorylate both Ins(1,4,5)P₃ and Ins(1,3,4,5)P₄, although the products of these reactions were not characterized [4]. We have now used HPLC to determine that *ipmk* catalyzed the phosphorylation of Ins(1,4,5)P₃ at both the 3- and 6-positions, forming Ins(1,3,4,5)P₄ and Ins(1,4,5,6)P₄ (Fig. 1). InsP₅ was also formed (Fig. 1) by further phosphorylation of both InsP₄ isomers (data not shown). This InsP₅ was shown to be the 1,3,4,5,6-isomer; no Ins(1,2,4,5,6)P₅ was formed (data not shown). The fact that Ins(1,4,5)P₃ is phosphorylated to Ins(1,4,5,6)P₄ by *ipmk* (which is 40 kDa [4]) suggests *ipmk* is equivalent to the Ins(1,4,5)P₃ 6-kinase activity of a 40 kDa protein that was partly purified from *S. cerevisiae* several years ago [15]. The authors of the latter study found that their preparations of partly purified Ins(1,4,5)P₃ 6-kinase also phosphorylated Ins(1,4,5,6)P₄ to Ins(1,3,4,5,6)P₅, but the latter 3-kinase activity was attributed to a different, contaminating enzyme [15]. In contrast, our data show it is *ipmk* that phosphorylates

Table 1
Levels of inositol phosphates in wild-type and *ipmkΔ* yeast

	DPM in wild-type	DPM in <i>ipmkΔ</i>	<i>ipmkΔ</i> /wild-type
InsP ₂	3 447 ± 571	248 502 ± 43 908	72
Ins(1,4,5)P ₃	921 ± 178	159 709 ± 11 642	173
Ins(1,4,5,6)P ₄	349 ± 38	0	–
Ins(1,3,4,5)P ₄	0	6 046 ± 316	–
X	490 ± 161	1 659 ± 582	3.4
Ins(1,3,4,5,6)P ₅	1 104 ± 300	159 ± 48	0.14
D/L-Ins(1,2,3,4,5)P ₅	148 ± 23	2 724 ± 631	18.4
D/L-Ins(1,2,4,5,6)P ₅	2 750 ± 852	0	–
InsP ₆	56 167 ± 7 502	519 ± 106	0.009
PP-InsP ₃	420 ± 78	133 ± 22	0.32
[PP] ₂ -InsP ₄	460 ± 53	65 ± 48	0.14

Data (mean ± S.E.M.) are taken from three experiments similar to those described in Fig. 2.

Ins(1,4,5,6)P₄ to Ins(1,3,4,5,6)P₅ (Fig. 1). *Ipmk* is also probably very similar to a 41 kDa kinase purified from *Schizosaccharomyces pombe* that phosphorylates Ins(1,4,5)P₃ to Ins(1,3,4,5,6)P₅, via Ins(1,4,5,6)P₄ and Ins(1,3,4,5)P₄ [16].

3.2. The inositol phosphate profile in wild-type and *ipmkΔ* strains of *S. cerevisiae*

The inositol phosphate profiles of the wild-type and *ipmkΔ* strains were compared. A major difference was the accumulation of large quantities of Ins(1,4,5)P₃ in the mutant strain, to levels that were 173-fold above those of the wild-type (Fig. 2; Table 1). Ins(1,4,5)P₃ accumulated because it continued to be produced from the yeast's ongoing PLC activity [5], but it was no longer phosphorylated by *ipmk*. The *ipmkΔ* yeast also had 72-fold higher levels of InsP₂ than did the wild-type (Fig. 2, Table 1), presumably reflecting some dephosphorylation of the excess Ins(1,4,5)P₃. In yeasts, Ins(1,4,5)P₃ has been proposed to be a precursor for the synthesis of InsP₅ and InsP₆ [5,16]. This hypothesis is supported by the observations that, relative to the wild-type yeast, the *ipmkΔ* strain contained 100-fold lower levels of InsP₆, and at least 10-fold lower levels of *D/L*-Ins(1,2,4,5,6)P₅ and Ins(1,3,4,5,6)P₅ (Fig. 2).




Fig. 2. Partisphere SAX HPLC analysis of inositol phosphates in wild-type and *ipmkΔ* yeast. [³H]inositol phosphates were resolved from [³H]inositol-labeled wild-type (A) and *ipmkΔ* cells (B), using a Partisphere SAX column (see Section 2); 1 ml fractions were collected. The inset to each panel shows the same data using a different y-axis scale. The structures of several inositol phosphates (Ins(1,4,5)P₃, Ins(1,3,4,5,6)P₅, *D/L*-Ins(1,2,3,5,6)P₅, InsP₆, PP-InsP₅ and [PP]₂-InsP₄) were assigned from their elution times matching those of corresponding, authentic ³H-labeled standards, which were separately determined in parallel HPLC runs. The *D/L*-Ins(1,2,3,5,6)P₅ was tentatively identified from its known [8] elution position between Ins(1,3,4,5,6)P₅ and *D/L*-Ins(1,2,4,5,6)P₅. The identification of Ins(1,3,4,5)P₄ and Ins(1,4,5,6)P₄ is described by Fig. 3. Peak 'X' was not identified. Data are representative of three experiments.




Fig. 3. SynChropak Q100 SAX HPLC analysis of inositol phosphates in wild-type and *ipmkΔ* yeast. [³H]InsP₄ isomers (filled circles) from wild-type (A) and *ipmkΔ* cells (B) were resolved using a SynChropak Q100 SAX column (see Section 2); 0.5 ml fractions were collected. Elution positions of authentic [¹⁴C]-labeled internal standards (open circles) of Ins(1,3,4,5)P₄, Ins(1,3,4,6)P₄ and Ins(1,4,5,6)P₄ are marked. In extracts prepared from wild-type cells (A), two ³H-labeled InsP₄ isomers were observed. One co-eluted with [¹⁴C]Ins(1,4,5,6)P₄ and the other (corresponding to peak 'X' in Fig. 2) eluted between standards of Ins(1,3,4,6)P₄ and Ins(1,3,4,5)P₄. In extracts prepared from *ipmkΔ* cells, one ³H-labeled peak co-eluted with a standard of [¹⁴C]Ins(1,3,4,5)P₄. Note that this SynChropak HPLC column does not resolve Ins(1,3,4,5)P₄ from the minor, contaminating peak 'X'. These two peaks were, however, separated on a Partisphere SAX column (Fig. 2). Data are representative of three independent experiments. Absolute elution times differ in A and B because of batch variation in the two SynChropak columns that were used for these experiments.

The profile of [³H]InsP₄ isomers was altered in the *ipmkΔ* yeast. Wild-type cells contained two InsP₄ peaks. One of these, which was not identified (peak 'X'), eluted between standards of Ins(1,3,4,6)P₄ and Ins(1,3,4,5)P₄ on a SynChropak SAX HPLC column (Fig. 3A). The other InsP₄ co-eluted with Ins(1,4,5,6)P₄ (Fig. 3A). In contrast, Ins(1,4,5,6)P₄ was absent in the *ipmkΔ* strain (Fig. 3B), due to the elimination of the Ins(1,4,5)P₃ 6-kinase activity of *ipmk*. In addition, the *ipmkΔ* cells were found to contain considerable quantities of another InsP₄ isomer, namely Ins(1,3,4,5)P₄ (on the SynChropak HPLC column, Ins(1,3,4,5)P₄ was contaminated with peak 'X' (Fig. 3B), but these two compounds were resolved when cell extracts were analyzed with a Partisphere SAX column (Fig. 2B)). Since Ins(1,3,4,5)P₄ was not detected in wild-type yeast (Fig. 3A), there is a dramatic up-regulation of Ins(1,3,4,5)P₄ levels in the absence of InsP₃ phosphorylation

by *ipmk*. Thus, *S. cerevisiae* synthesizes Ins(1,3,4,5)P₄ using a different inositol phosphate kinase that by-passes *ipmk*. Furthermore, the persistence of low levels of InsP₆ in the *ipmk*Δ yeast suggests that, to a limited extent, this auxiliary metabolic pathway extends to the synthesis of InsP₆. D/L-Ins(1,2,3,4,5)P₅ might participate in this alternate metabolic route, since its levels increased 18-fold in the *ipmk*Δ cells (Table 1). It has previously not been considered that there might be more than one pathway of InsP₆ synthesis in yeast.

We also identified both PP-InsP₅ and [PP]₂-InsP₄ in *S. cerevisiae* (Fig. 1). In mammalian cells, these ‘high-energy’ diphosphoinositol polyphosphates are candidate molecular switches [17,18] that are rapidly metabolized through substrate cycles that are regulated by cAMP, cGMP and Ca²⁺ [8,19]. PP-InsP₅ and [PP]₂-InsP₄ are present at 100-fold lower levels than InsP₆, as is the case in higher eukaryotes [17]. This is the first time that PP-InsP₅ and [PP]₂-InsP₄ have been identified in any yeast, although their presence was anticipated, following earlier identification of a kinase from *S. cerevisiae* that synthesizes PP-InsP₅ [4] and the discovery of a diphosphoinositol polyphosphate phosphatase from the same organism [12].

It should be noted that the *ipmk*Δ strain of yeast grew more slowly than the wild-type at both 23°C and 30°C, and growth was completely arrested at 37°C ([2] and data not shown). Despite this temperature-sensitive growth phenotype, all of the differences in the inositol phosphate profile between wild-type and *ipmk*Δ yeast strains that were observed at 37°C (Figs. 2 and 3) were also observed at 23°C (data not shown).

3.3. Inositol phosphates and the regulation of nuclear mRNA export

Recently, York et al. [5] described a mutant strain of yeast, named *gsl3*, that displayed changes in inositol phosphate turnover that, in some cases, are similar to those of our *ipmk*Δ strain. These include decreases in levels of InsP₆, accompanied by increases in levels of InsP₂, Ins(1,4,5)P₃ and InsP₄ [5]. The protein product that was disrupted in the *gsl3* strain was not identified, although it was suggested that it might be either (i) a regulator of kinase activities against InsP₃ and InsP₄, or (ii) a multifunctional InsP₃/InsP₄ kinase [5]. Our data indicate for the first time that deletion of a genuine InsP₃/InsP₄ kinase does promote the changes in inositol phosphate turnover that typified the *gsl3* strain [5]. Thus, our data are consistent with the *gsl3* strain being equivalent, and probably identical, to the *ipmk*Δ strain. York et al. [5] reported that the *gsl3* variant was one of three yeast strains displaying impaired mRNA export from the nucleus. Thus, it was important to determine if mRNA export was also inhibited in our own *ipmk*Δ mutant.

Poly(A)⁺ RNA was detected with a fluorescein isothiocyanate-coupled antibody against digoxigenin. In wild-type cells, a diffuse signal was distributed throughout the cell (Fig. 4). However, the *ipmk*Δ cells contained more punctate signals that were restricted to the nuclei, as revealed by coincident staining with 4',6'-diamidino-2-phenylindole (Fig. 4). These results are consistent with mRNA export from the nucleus being strongly impaired in the *ipmk*Δ yeast, although we cannot exclude the possibility that there may also be some decreased stability of cytoplasmic mRNA. mRNA export itself comprises a series of molecular events including RNA syn-




Fig. 4. Nuclear mRNA export in wild-type and *ipmk*Δ yeast. The upper panels show poly(A)⁺ RNA labeling. The lower panels show the same fields processed for DAPI staining. Data are representative of three experiments.

thesis, polyadenylation and capping, ribonucleoprotein targeting to the pore complex as well as transport through it [20]. A defect in any of these individual steps could account for the loss of cytoplasmic poly(A)⁺ in the *ipmk*Δ cells (Fig. 4).

Ipmk was first discovered as a product of the *ARGR3* gene [4], which controls the transcription of enzymes involved in arginine metabolism [1–3]. The latter workers have also indicated that *ARGR3* is pleiotropic, although it was unclear what molecular mechanisms underlie the additional gene functions [2]. Therefore, our demonstration that disruption of this same gene both affects mRNA dynamics and causes global changes in inositol phosphate turnover represents major findings in our study.

How might these changes in inositol phosphate turnover regulate nuclear mRNA export in yeast? [InsP₆] may be one factor that is important; other genetic mutations in *S. cerevisiae* that also impaired mRNA export, namely, deletion of either the Ins(1,3,4,5,6)P₅ 2-kinase or PLC, both have in common with the *ipmk*Δ cells a dramatic decrease in InsP₆ levels [5]. However, our results indicate that it may be an oversimplification to attribute a reduced rate of mRNA export to a decrease in [InsP₆], in part because we have shown that InsP₆ does not represent a metabolic end-point in yeast. The concentrations of two InsP₆ metabolites, namely, PP-InsP₅ and [PP]₂-InsP₄, also decrease in the *ipmk*Δ yeast (Table 1). Moreover, the *ipmk*Δ cells also have substantial increases in levels of D/L-Ins(1,2,3,4,5)P₅, Ins(1,3,4,5)P₄ and Ins(1,4,5)P₃, as well as decreased concentrations of Ins(1,4,5,6)P₄ and D/L-Ins(1,2,4,5,6)P₅ (Table 1). It could be that one or more of these other polyphosphates, rather than InsP₆ itself, are the compounds that play an important role in mRNA export. In particular, it is notable that the turnover of the diphosphoinositol phosphates is generally a rapid, ongoing activity that demands a considerable investment of cellular energy [17]; nuclear mRNA export is also an energy-intensive process [20]. In any case, the particular importance to the yeast cell of PP-InsP₅ and [PP]₂-InsP₄ is indicated by the fact that, in

the face of 100-fold decreases in the levels of InsP₆, the yeast cells apparently change the poise of the kinase/phosphatase substrate cycles that turn over these diphosphoinositol polyphosphates; thus, the ratio of PP-InsP₅:InsP₆ increased nearly 40-fold, from a value of 0.007 in the wild-type cells to 0.26 in the *ipmkΔ* yeast (Table 1).

Our data establish that complex changes in inositol phosphate metabolism are associated with decreased efficiency of nuclear export of mRNA. Analysis of signal transduction by inositol phosphates in the nuclei or at the level of the nuclear pore complex may elucidate the mechanism of nuclear mRNA transport at the molecular level.

Acknowledgements: We are grateful to Adele M. Snowman for her skillful technical assistance. Supported by USPHS Grant MH18501 (S.H.S.) and Research Scientist Award DA00074 (S.H.S.).

References

- [1] Bercy, J., Dubois, E. and Messenguy, F. (1987) *Gene* 55, 277–285.
- [2] Dubois, E. and Messenguy, F. (1994) *Mol. Gen. Genet.* 243, 315–324.
- [3] Qui, H.F., Dubois, E., Bröen, P. and Messenguy, F. (1990) *Mol. Gen. Genet.* 222, 192–200.
- [4] Saiardi, A., Erdjument-Bromage, H., Snowman, A., Tempst, P. and Snyder, S.H. (1999) *Curr. Biol.* 9, 1323–1326.
- [5] York, J.D., Odom, A.R., Murphy, R., Ives, E.B. and Wentz, S.R. (1999) *Science* 285, 96–100.
- [6] Güldener, U., Heck, S., Fiedler, T., Beinbauer, J. and Hegemann, J.H. (1996) *Nucleic Acids Res.* 24, 2519–2524.
- [7] Shears, S.B. (1997) in: *Signalling by Inositides: A Practical Approach* (Shears, S.B., Ed.), pp. 33–52, Oxford University Press, Oxford.
- [8] Glennon, M.C. and Shears, S.B. (1993) *Biochem. J.* 293, 583–590.
- [9] Balla, T., Sim, S.S., Iida, T., Choi, K.Y., Catt, K.J.J. and Rhee, S.G. (1991) *J. Biol. Chem.* 266, 24179.
- [10] Stephens, L.R. and Downes, C.P. (1990) *Biochem. J.* 265, 435–452.
- [11] Stephens, L.R., Hawkins, P.T., Stanley, A.F., Moore, T., Poyner, D.R., Morris, P.J., Hanley, M.R., Kay, R.R. and Irvine, R.F. (1991) *Biochem. J.* 275, 485–499.
- [12] Safrany, S.T., Ingram, S.W., Cartwright, J.L., Falck, J.R., McLennan, A.G., Barnes, L.D. and Shears, S.B. (1999) *J. Biol. Chem.* 274, 21735–21740.
- [13] Hughes, P.J., Hughes, A.R., Putney Jr., J.W. and Shears, S.B. (1989) *J. Biol. Chem.* 264, 19871–19878.
- [14] Amberg, D.C., Goldstein, A.L. and Cole, C.N. (1992) *Genes Dev.* 6, 1173–1189.
- [15] Estevez, F., Pulford, D., Stark, M.J.R., Carter, A.N. and Downes, C.P. (1994) *Biochem. J.* 302, 709–716.
- [16] Ongusaha, P.P., Hughes, P.J., Davey, J. and Michell, R.H. (1998) *Biochem. J.* 335, 671–679.
- [17] Safrany, S.T., Caffrey, J.J., Yang, X. and Shears, S.B. (1999) *Biol. Chem.* 380, 945–951.
- [18] Voglmaier, S.M., Bembenek, M.E., Kaplin, A.I., Dormán, G., Olszewski, J.D., Prestwich, G.D. and Snyder, S.H. (1996) *Proc. Natl. Acad. Sci. USA* 93, 4305–4310.
- [19] Safrany, S.T. and Shears, S.B. (1998) *EMBO J.* 17, 1710–1716.
- [20] Nakielnny, S. and Dreyfuss, G. (2000) *Cell* 99, 677–690.